Healthcare Industry News: NanoCrystal
News Release - February 6, 2008
NANOSTIM(TM) Synthetic Bone Paste for Orthopedic Procedures Now Available in EuropeMEMPHIS, Tenn.--(HSMN NewsFeed)--Medtronic, Inc. (NYSE: MDT ), today announced the distribution of NANOSTIM™ Synthetic Bone Paste for use in surgical procedures in the European Union and other markets outside the United States. This nanohydroxyapatite-based bone graft substitute provides a supporting structure for new bone formation, aiding bone healing in places where voids or gaps exists in the bone. NANOSTIM Synthetic Bone Paste can be filled into defects regardless of their shape and stays in place keeping close contact to the surrounding bone.
The patented NANOSTIM Synthetic Bone Paste, consisting of highly pure microscopic crystals called NanoCrystals, does not harden after application in bone voids. NANOSTIM Synthetic Bone Paste is also free of exothermic heating, a chemical reaction in the body that can lead to the destruction of bone cells.
“Our patients achieved successful bone formation when we used NANOSTIM Synthetic Bone Paste,” said Reinhart Schnettler, M.D., Department of Trauma Surgery, University Hospital Giessen-Marburg GmbH in Giessen, Germany. “It’s easy to handle in the operating room and its osteoconductive properties make it an effective bone void filler.”
About the Spinal and Biologics Business at Medtronic
The Spinal and Biologics business at Medtronic is based in Memphis, Tenn. It is the global leader in today’s spine market and is committed to advancing the treatment of spinal conditions. The Spinal and Biologics business works with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for neurological, orthopaedic, dental and spinal conditions. Medtronic is committed to developing affordable, minimally-invasive procedures that provide lifestyle-friendly surgical therapies. More information about the company and its treatment therapies can be found at www.medtronicspinal.com and its patient-education Web sites, www.back.com, www.iscoliosis.com, www.maturespine.com and www.necksurgery.com.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsFDA Approves First-of-its-Kind SenSight(TM) Directional Lead System for DBS Therapy
Medtronic Gains FDA Clearance of UNiD(TM) Patient-Specific Rods for Use with CD Horizon(TM) Solera(TM) Voyager(TM) and Infinity(TM) OCT Spinal Systems
Medtronic to Stop Distribution and Sale of HVAD(TM) System